The study demonstrates cell-specific localization of PDE5 in various rat tissues, suggesting the presence of a cGMP/PDE5 pathway in these tissues.
Answers are grounded in this paper and cite their sources.
Rat PDE5 localization should not guide clinical decisions; leaves open cGMP pathway roles in cerebellum, kidney, and pancreas.
We raised a polyclonal antibody against maltose binding protein fusion human cGMP-binding, cGMP-specific phosphodiesterase (PDE5) produced in E. coli. This antibody immunoreacted specifically with recombinant human and rat PDE5 proteins expressed in transfected COS-7 cells and with a native form of PDE5 in extracts of rat platelets, lung, and cerebellum. Immunohistochemical analysis showed that the anti-PDE5 antibody detected immunoactive materials in Purkinje cell layers of the cerebellum, proximal renal tubules, collecting renal ducts, and epithelial cells of pancreatic ducts in rats. Reverse transcriptase-polymerase chain reaction analysis demonstrated that PDE5 transcripts are also present in rat cerebellum, kidney, and pancreas. Here we described a cell-specific localization of PDE5 in various rat tissues, suggesting the possibility of the presence of a cGMP/PDE5 pathway in these tissues.
No takes yet. Share an insight, caveat, or question.
Kotera et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: